Veterinary Active Pharmaceutical Ingredients Manufacturing Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Veterinary API Manufacturing Market is segmented by Product (Antiparasitic, Anti-infectives, Vaccines, NSAIDs, Others (Biologics, Vitamins, Gastroenteric, Cardiovascular, Beta Agonists)), By Synthesis Type (Chemical Based API, Biological API, Highly potent API (HPAPI)) By Service Type (In House, Contract Outsourcing) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 7.1 %
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Veterinary API Manufacturing Market is projected to register a CAGR of 7.10% during the forecast period (2022-2027).

The COVID-19 epidemic has had a significant impact on the market. There have been a few COVID-19 infections in pets around the world. COVID-19 is caused by a virus that can be transmitted from people to animals through intimate contact. COVID-19 is unlikely to transmit from animals to humans. Infection with the virus that causes COVID-19 can cause significant sickness in pets, but this is quite rare. Thus, the COVID-19 infection increased the chances of infections in many animals which is expected to drive the market growth.

The factors expected to drive the market growth include the increasing prevalence of zoonotic diseases, increasing animal population and pet ownership, and rising number of veterinarians and veterinary visits. The market is highly propelled by the increasing pet expenditures and number of veterinary visits and high prevalence of zoonotic diseases. Human-animal connection is necessary for existence and cannot be removed soon, making zoonoses easier to spread. Human-animal cohabitation is more common in poorer nations, particularly among rural populations. This inextricable relationship is evidenced by the higher occurrence of zoonoses in these countries. The Indian Journal of Medical Research in 2021 stated that animals are responsible for 70% of emerging infectious diseases; every year, 5 new diseases are generated, three of which are of animal origin, and zoonotic infections account for 80% of agents with potential bioterrorism use. This expected to support market growth.

The need for veterinary Active Pharmaceutical Ingredients is expanding as the variety of oral formulations for diverse veterinary medications grows. Nonsteroidal anti-inflammatory medications (NSAIDs) are the most common. Process synthesis, which aids in the acceleration of the manufacturing process for active medicinal components, is becoming more popular among manufacturers. In addition, the emergence of biologically produced and high potency APIs, which act on target cells with a significantly lower dose than typical APIs, is projected to drive market expansion.

Supportive government policies are driving the manufacturing of veterinary active pharmaceutical ingredients. For instance, initiatives, such as Pharma Vision 2020 by the Indian government, which is aimed at developing the country’s capabilities in the fields of drug discovery, innovation, and drug manufacturing, is expected to have a positive impact on the political scenario of the market. 

Market players are implementing several strategic initiatives such as geographical expansion. For instance, in November 2020, Ofichem Group expanded with a new office in Hangzhou, China. This supported the company’s growth strategy. In May 2018, Zoetis expanded its manufacturing and supply facility in Kalamazoo to provide high-quality medicines for veterinarian and livestock farmer customers. This is expected to fuel the market growth.

Scope of the Report

As per the scope of this report, the biologically active component of a medicine used to treat animals as a tablet, pill, cream, or injection that causes the desired effects is known as the Veterinary Active Pharmaceutical Ingredient (API). The component of medicine that generates the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies have various active substances that cure distinct symptoms or work in different ways.

The Veterinary API Manufacturing Market is segmented by Product (Antiparasitic, Anti-infectives, Vaccines, NSAIDs, Others (Biologics, Vitamins, Gastroenteric, Cardiovascular, Beta Agonists)), By Synthesis Type (Chemical Based API, Biological API, Highly potent API (HPAPI)) By Service Type (In House, Contract Outsourcing) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments. 

By Product
Antiparasitic
Anti-infectives
Vaccines
NSAIDs
Others
By Synthesis Type
Chemical Based API
Biological API
Highly Potent API (HPAPI)
By Service Type
In House
Contract Outsourcing
Contract Development
Contract Manufacturing
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Vaccine Segment is Expected to Hold a Major Market Share in the Veterinary API Manufacturing Market

The increased need for vaccines due to the high frequency of chronic diseases in animals is credited with the segment's growth. Furthermore, rising livestock populations and animal husbandry, as well as the commercialization of animal products, are likely to raise vaccine demand, propelling the segment forward. The increased demand for animal-derived food products is driving the expansion of this market, as is the rise in the companion animal population, rising prevalence of zoonotic diseases, and activities by various government agencies and animal groups to protect animal health. The high storage cost of vaccinations, on the other hand, is limiting market expansion.

The rising number of cattle disease outbreaks and the ever-increasing livestock population are the primary reasons for ruminants' widespread popularity. Meat, protein, food, milk, and other commercial items such as wool and leather are all derived from animals. Rabies vaccinations, equine influenza virus vaccines, and foot and mouth disease vaccines are the most commonly used animal vaccines, which inhibit the transfer of infectious pathogens by replicating naturally acquired immunity. Growing worries about food security, as well as increased animal husbandry, are driving up demand for livestock vaccines. Globally, increased demand for animal products has resulted in increased livestock output.

The demand for animal products is increasing due to several causes such as changing food choices as a result of changing lifestyles and population increase. These elements are assisting the market's expansion. The constant development of technologically superior vaccines, as well as the spread of cattle diseases, have all contributed to changing market dynamics.

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global Veterinary API Manufacturing Market. Zoonoses pose a concern to human health because animals are frequently the natural source of disease. The rising frequency of zoonotic diseases is a major factor driving market expansion. 

According to the U.S. Department of Agriculture, there were 103.0 million cattle and 32.1 million beef cows in the U.S. in July 2020, and this number is expected to grow substantially in the coming years. Moreover, factors such as rise in R&D investments, advancements in procedures, high pet adoption rates, increased consumption of meat, and mandatory vaccination are anticipated to boost the market growth during the forecast period.

Favorable reimbursement programs are boosting demand for veterinary medication, giving the industry in this region a solid foundation for growth. The high frequency of livestock and zoonotic illnesses, which result in large-scale animal mortality, can lead to large lose. In addition, the market is predicted to rise due to the huge number of well-established pharmaceutical companies that are continually working to expand the commercialization of their vaccines and expand their geographic reach. 

Furthermore, the rising frequency of canine illnesses, which is raising vaccination adoption for the same, and the growing pet population in the United States are two significant factors contributing to the regional market's rise. The expanding popularity of pets, the development of leading vaccination players, increased product availability, and investments in manufacturing facilities in the region are all supporting this market's growth.

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Analysis

Competitive Landscape

The Veterinary API Manufacturing Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group, Menadiona, SUANFARMA, NGL Fine-Chem Ltd., FIS - Fabbrica Italiana Sintetici S.p.A., Zoetis, Indukern, Huvepharma, ourofino.

Recent Development

  • In November 2020, Sequent Scientific stated its completion in the acquisition of 40% stake in Provet Veteriner Urunleri San. Ve Tic. In Turkey
  •  In November 2020, Alivira Animal Health Ltd. acquired Provet Veteriner Urunleri San. Ve Tic. A. S. in Turkey.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions & Market Defination

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Zoonotic Diseases

      2. 4.2.2 Increasing Animal Population And Pet Ownership

      3. 4.2.3 Rising Number of Veterinarians and Veterinary Visits

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness and High Cost of Animal Care

      2. 4.3.2 Stringent Government Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 Antiparasitic

      2. 5.1.2 Anti-infectives

      3. 5.1.3 Vaccines

      4. 5.1.4 NSAIDs

      5. 5.1.5 Others

    2. 5.2 By Synthesis Type

      1. 5.2.1 Chemical Based API

      2. 5.2.2 Biological API

      3. 5.2.3 Highly Potent API (HPAPI)

    3. 5.3 By Service Type

      1. 5.3.1 In House

      2. 5.3.2 Contract Outsourcing

        1. 5.3.2.1 Contract Development

        2. 5.3.2.2 Contract Manufacturing

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Alivira Animal Health Limited

      2. 6.1.2 Excel Industries Limited

      3. 6.1.3 Ofichem Group

      4. 6.1.4 Menadiona

      5. 6.1.5 SUANFARMA

      6. 6.1.6 NGL Fine-Chem Ltd.

      7. 6.1.7 FIS - Fabbrica Italiana Sintetici S.p.A.

      8. 6.1.8 Zoetis

      9. 6.1.9 Indukern

      10. 6.1.10 Huvepharma

      11. 6.1.11 ourofino

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market market is studied from 2019 - 2027.

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market is growing at a CAGR of 7.1% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Excel Industries Limited, Alivira Animal Health Limited , NGL Fine-Chem Ltd, Zoetis, Indukern are the major companies operating in Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!